Some studies suggest an atherogenic role, while others suggest a protective role for atherosclerosis.[7] Therefore, the function of IL-17 or IL-17R inhibitors on psoriatic patients with atherosclerosis remains controversial. The gene discussed is IL17A; the disease is atherosclerosis.